The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.
about
A Review of Management of Inflammation in the HIV PopulationAlcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study.Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapyAttenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation.HIV infection of hepatocytes results in a modest increase in hepatitis C virus expression in vitroRedoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.Diabetes in the time of HIV.The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population.Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV InfectionLiver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles.Hepatotoxicity during Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living with HIV with Severe Immunosuppression: a Secondary Analysis of a Multi-country Open-label Randomized Controlled Clinical Trial.
P2860
Q28078962-CE4C84BF-491E-4368-A106-72A37E454F90Q33787607-A6D12559-11E6-4888-8AD1-C057110FE738Q33939760-34257EBC-2A8E-4B8B-9E69-125CC9976C3BQ34300102-3E10AD52-6228-41C0-B431-61966B122A83Q35105824-4B93FE17-53E5-45DE-9A26-68A87D438F1EQ35682519-DD9BCB6D-0BA6-4460-B7FB-36DED5CDF0E9Q36107867-53718625-2434-4740-9948-420907AE9767Q36187833-72558242-3EA4-4F1B-8F09-5415695999EEQ37013998-9E5EB2DF-8E04-488F-8FB5-5CF6E7C01667Q38606313-B2AE9598-435E-49CD-B407-95D9914C55EAQ40750320-255DA57F-731C-4C22-BA8A-60DBEA8EEC5DQ41392118-4ECC7481-29C8-47FC-8FE6-A9892FB8E78FQ41466494-FD21F7D3-EC67-484E-A2A5-38F0BDCC3A93Q47553930-16763F28-CF85-41C1-AB3E-CD32C12441DBQ50059794-105D3DE8-C9B0-4D48-9829-0103CF0A248C
P2860
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@ast
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@en
type
label
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@ast
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@en
prefLabel
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@ast
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@en
P2093
P2860
P1476
The effect of HIV infection, i ...... e risk of hepatic dysfunction.
@en
P2093
Charles P Quesenberry
Chun R Chao
Daniel B Klein
Lanfang Xu
Leo B Hurley
Michael A Horberg
Michael J Silverberg
Wendy A Leyden
William J Towner
P2860
P304
P356
10.1097/QAI.0B013E31824E9EF2
P407
P577
2012-07-01T00:00:00Z